1020576-91-3Relevant academic research and scientific papers
HETEROCYCLIC COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS FOR THE TREATMENT OF HYPERPARATHYROIDISM, CHRONIC RENAL FAILURE AND CHRONIC KIDNEY DISEASE
-
Page/Page column 42, (2015/11/16)
The invention relates to heterocyclic compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their pharmaceutical compositions for use in medicine for the treatment of diseases or disorders associated with the modulation of calcium sensing receptor modulators (CaSR), like e.g. hyperparathyroidism, chronic renal failure and chronic kidney disease and their complications.
Conformationally constrained farnesoid X receptor (FXR) agonists: Heteroaryl replacements of the naphthalene
Bass, Jonathan Y.,Caravella, Justin A.,Chen, Lihong,Creech, Katrina L.,Deaton, David N.,Madauss, Kevin P.,Marr, Harry B.,McFadyen, Robert B.,Miller, Aaron B.,Mills, Wendy Y.,Navas III, Frank,Parks, Derek J.,Smalley Jr., Terrence L.,Spearing, Paul K.,Todd, Dan,Williams, Shawn P.,Wisely, G. Bruce
supporting information; experimental part, p. 1206 - 1213 (2011/04/16)
To improve on the drug properties of GSK8062 1b, a series of heteroaryl bicyclic naphthalene replacements were prepared. The quinoline 1c was an equipotent FXR agonist with improved drug developability parameters relative to 1b. In addition, analog 1c lowered body weight gain and serum glucose in a DIO mouse model of diabetes.
